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In an era of increasing antibiotic resistance, growing clinical need for newdrugs, and few leadmolecules, new
research is helping to identify new targets and the mechanism of action of lead molecules.There is a pressing need for new antibi-
otics. Resistance has emerged to every
class of existing antibiotic in clinical
use and is widespread in hospitals,
the community, and the environment
(D’Costa et al., 2006; Livermore, 2009).
Paradoxically, despite this need for new
anti-infective drugs, the pharmaceutical
sector has reduced efforts in this area
for a number of complex reasons ranging
from regulatory hurdles and return-on-
investment issues to challenging scientific
barriers to discovering new antibiotics
using the target-based high-throughput
paradigm of modern drug discovery
(Payne et al., 2007).
Researchers at Merck, however, are in
the fray and using new technology to
discover new drug leads. Specifically,
they have applied an inducible gene
silencing approach by means of antisense
RNA as a powerful tool in antibiotic
discovery research. The approach was
first reported by this group in the discovery
and characterization of platensimycin,
a new antibiotic natural product discov-
ered in a program to identify inhibitors of
bacterial type II fatty acid biosynthesis in
a whole-cell screen of Staphylococcus
aureus (Wang et al., 2006). This antibiotic
represented a new chemical scaffold
and targeted a largely untapped bacterial
essential enzyme target in FabF.
The Merck group report in a recent
issue ofChemistry & Biology the optimiza-
tion of an antisense profiling platform for
the discovery of the mechanism of action
(MOA) of antibiotics (Donald et al., 2009)
and apply it in the characterization of
new agents that synergize with carbape-
nem antibiotics in methicillin-resistant
S. aureus (MRSA) (Huber et al., 2009). The
platform generates antisense-induced
strain sensitivity (AISS) profiles for anti-
bacterial compounds in an S. aureusbackground that informs on the MOA of
antibiotics.
Determining the MOA of bioactive
molecules such as antibiotics is not trivial.
As a result, a number of techniques
have been used to identify the macromo-
lecular targets of these compounds. For
example, serial culturing of sensitive
strains with sublethal doses of many anti-
biotics can enrich for resistant strains
with mutations in target-encoding genes
that result in resistance. Sequencing of
predicted target genes or even whole
genomes (Andries et al., 2005) and
comparing the sequences from resistant
and sensitive organisms can reveal likely
targets or pathways. Direct biochemical
identification of targets either by affinity
chromatography or by covalent modifica-
tion of the antibiotic and target (if the
chemistry is compatible) has also been
used, but requires chemical modification
of the compounds (which may abolish
antimicrobial activity) and downstream
protein sequencing of potential targets.
Overexpression of genes followed by
selection for resistance has also proven
to be useful by increasing target gene
dosage, which can reveal both target ID
and new potential mechanisms of resis-
tance, such as efflux (Li et al., 2004).
The yeast research community has
been especially successful in identifying
targets for bioactive compounds using
whole-cell chemical genomics platform
approaches to zero in on targets using
multicopy suppression, transcript, and
gene deletion microarrays as well as
haploinsufficiency (gene suppression)
approaches. The latter technique results
in reduced gene dose and consequent
hypersensitivity to antibiotics. The AISS
approach works by the same principle
in S. aureus (Donald et al., 2009). The
Merck researchers have focused on 245Cell Host & Microbe 6, Sstrains expressing antisense transcripts
to known essential genes. Antisense
expression is xylose inducible, and 24
pools of strains (selected for their uniform
growth response to discrete concentra-
tions of xylose) are exposed to antibiotic
or DMSO control for 20 generations.
Cells are then lysed and subjected to
multiplex PCR, with antisense markers
and their products analyzed and quanti-
fied by capillary electrophoresis, gener-
ating a profile of strains that are either
unaffected or depleted upon compound
exposure. The latter should inform directly
or indirectly on the antibiotic target.
The whole-cell AISS platform was used
to examine the effects of 59 known antibi-
otics to validate the approach (Donald
et al., 2009). The antibiotics clustered
into four groups that can be broadly clas-
sified as activity versus (A) replication
and transcription, (B) cell wall/plasma
membrane, (C) lipid biosynthesis (includ-
ing bactericidal aminoglycosides), and
(D) protein synthesis. The clustering of
bactericidal aminoglycosides that are
traditionally thought of as protein syn-
thesis inhibitors with lipid biosynthesis
inhibitors such as platensimycin is consis-
tent with the growing evidence that amino-
glycosides act by indirectly impacting
membranes (Kohanski et al., 2008).
Furthermore, each group is subdivided
into classes that reflect their MOA, e.g.,
fluoroquinolones distinct from DNA inter-
calators in group A, vancomycin and risto-
cetin distinct from teicoplanin in group B,
etc. The result is a powerful template to
assess MOA of unknown antibiotics and
to reassess the activity of known ones.
In the second paper from the Merck
group, the AISS platform is used to
provide information on the MOA of
compounds identified in a screen to
identify compounds that synergize witheptember 17, 2009 ª2009 Elsevier Inc. 197
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Previewscarbapenems in activity against MRSA
(Huber et al., 2009). MRSA is a growing
problem in both the clinic and the commu-
nity, and successful treatment is often
extremely challenging. In fact, in 2005,
almost 19,000 patients died in the U.S.
from MRSA infection, more than the
number of HIV/AIDS patients the same
year (Klevens et al., 2007). MSRA is insen-
sitive to carbapenem antibiotics as a result
of the expression of penicillin-binding
proteins PBP2A and PBP2. The Merck
group screened their chemical library
in a whole-cell phenotype assay for
compounds that potentiated the activity
of the carbapenem ertapenem. The result
was the identification of two structurally
related indoles that synergize with ertape-
nem to kill MRSA, but not b-lactam-sensi-
tive S. aureus. The compounds showed
weak antibiotic activity as single agents,
but when combined with a carbapenem,
they showed excellent antimicrobial
activity. There is growing interest in
compound combinations that selectively
target difficult biological targets (Keith
et al., 2005). Antibiotic combinations
have long been a mainstay of anti-infec-
tive therapy and in fact are sometimes
packaged together (e.g., Bactrim is a
combination of sulfamethoxazole and
trimethoprim). Furthermore, inhibitors of
antibiotic resistance enzymes are pack-
aged with b-lactam antibiotics (e.g.,
Augmentin). However, these combina-
tions are often the result of postdiscov-
ery efforts. In the current paper, the
screen is designed to identify antibiotic198 Cell Host & Microbe 6, September 17, 2synergizing compounds a priori, and
the approach yielded compounds that
unexpectedly synergize with ertapenem,
so-called syncretic combinations (Keith
et al., 2005).
With the two compounds in hand, the
Merck group then used the AISS platform
to establish MOA (Huber et al., 2009). The
results indicated that these ertapenem-
synergizing compounds clustered with
cell wall active compounds and specifi-
cally that a gene of unknown function,
SAV1754, was a potential target. Using
a series of downstream experiments,
including peptidoglycan analysis by fluo-
rescence microscopy, genetic depletion
of the gene, and analysis of resistant
mutants, the authors conclude that
SAV1754 is indeed the target of the carba-
penem-synergizing molecules in MRSA.
Analysis of the predicted SAV1754 protein
revealed similarity to the recently identi-
fied lipid II flippase MurJ in E. coli, which
moves the assembled peptidoglycan
monomer from inside the cell to the exte-
rior, where it is grafted onto the cell wall
by enzymes such as PBP2.
The combined papers (Donald et al.,
2009; Huber et al., 2009) therefore provide
a new platform for the identification of
the MOA of antibiotics and other bio-
active compounds and a proof-of-prin-
ciple screen for antibiotic synergizing
compounds in MRSA. Furthermore, they
generate a new lead molecule class of
antibiotics and identify a new druggable
target in a major human pathogen. In
short, they represent a tour de force in009 ª2009 Elsevier Inc.antibiotic drug discovery—a field that is
in need of some good news stories.
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